Jaarbeurs Utrecht, Netherlands
Booth: XXX
Connect with Ncardia at the Safety Pharmacology Society (SPS) Annual Meeting to meet the solution that’s reshaping predictive toxicology and preclinical safety testing: iPSC-based platforms. Our high-throughput, human-relevant models are built to meet the rigorous demands of cardiac, neurological, and stem cell research — offering the precision and scalability required for modern safety pharmacology.
Let’s meet at SPS 2025 to discuss how our discovery services and iPSC-derived models can support your next study from early screening to regulatory submission.
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.